Study: Abbvie M25-998

Written By Patrick Smith

Are you living with overweight or obesity and do not have diabetes? 

If so, you may be eligible to participate in a clinical research study evaluating an amylin analog (ABBV-295) for weight management. 

ABOUT THE STUDY

This is a Phase 2 study assessing how ABBV-295 affects food intake and body weight. 

WHO MAY QUALIFY? 

You may be eligible to participate if you meet all the following: 

  • Age 18 to 75 years  

  • Body mass index (BMI) of 27 or higher (classified as overweight or obesity) 

  • Do not have diabetes 

  • Have not used any GLP-1-based medication — including pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo) or any other weight loss medication within the past 6 months 

  • Have never had surgery for treatment of obesity

INTERESTED IN LEARNING MORE? 

Click below to complete a short questionnaire to see if you may be eligible.
(JotForm link)

Patrick Smith
Previous

Study: Genentech CC 46372
Next

This post will be deleted